Chemistry:Dotinurad
From HandWiki
Short description: Drug
 | |
| Clinical data | |
|---|---|
| Trade names | Urece |
| Other names | FYU-981 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H9Cl2NO4S |
| Molar mass | 358.19 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.[1][2] It was developed by Fuji Yakuhin and approved for use in Japan in 2020.[2][3] The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.[3][4]
Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity by inhibiting URAT1/SLC22A12 receptor. It is a structural analog of Benzbromarone. [5][6]
References
- ↑ "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology 24 (Suppl 1): 1–5. March 2020. doi:10.1007/s10157-019-01811-9. PMID 31754883.
- ↑ 2.0 2.1 "List of Approved Products". Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000235289.pdf.
- ↑ 3.0 3.1 "Fortress takes on dotinurad in USA and Europe". November 5, 2020. https://www.thepharmaletter.com/in-brief/brief-fortress-biotech-takes-on-dotinurad-in-usa-and-europe.
- ↑ "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". May 10, 2021. https://www.biospace.com/article/releases/fortress-biotech-announces-exclusive-license-agreement-with-fuji-yakuhin-to-develop-dotinurad-in-north-america-and-europe/.
- ↑ "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics 371 (1): 162–170. October 2019. doi:10.1124/jpet.119.259341. PMID 31371478.
- ↑ "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters 11 (10): 2017–2023. October 2020. doi:10.1021/acsmedchemlett.0c00176. PMID 33062187.
 |  |
